We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+20.38%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$101M
AUM Growth
–
Cap. Flow
+$93.1M
Cap. Flow %
92.16%
Top 10 Hldgs %
37.84%
Holding
57
New
57
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$4.48M
2
INCY icon
Incyte
INCY
+$3.98M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.64M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.56M
5
CELG
Celgene Corp
CELG
+$3.48M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 70.4%
2 Miscellaneous 29.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
26
DELISTED
Clovis Oncology, Inc.
CLVS
$1.51M 1.5%
+27,000
New +$1.42M
HOLX
27
DELISTED
Hologic
HOLX
$1.42M 1.4%
+53,000
New +$1.37M
XNPT
28
DELISTED
XENOPORT, INC.
XNPT
$1.33M 1.32%
+152,000
New +$1.12M
STML
29
DELISTED
Stemline Therapeutics, Inc.
STML
$1.2M 1.19%
+70,400
New +$1.02M
ALKS icon
30
Alkermes
ALKS
$8.2B
$1.15M 1.14%
+19,631
New +$1,000K
TENX icon
31
Tenax Therapeutics
TENX
$82M
$956K 0.95%
+8
New +$968K
ARRY
32
DELISTED
Array Biopharma Inc
ARRY
$946K 0.94%
+200,000
New +$791K
KBIO
33
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$945K 0.94%
+68,308
New +$975K
VCEL icon
34
Vericel Corp
VCEL
$2.11B
$861K 0.85%
+283,270
New +$806K
MNTA
35
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$843K 0.83%
+70,000
New +$800K
EIGR
36
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$828K 0.82%
+94
New +$546K
MACK
37
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$814K 0.81%
+9,152
New +$667K
OCRX
38
DELISTED
Ocera Therapeutics, Inc.
OCRX
$781K 0.77%
+122,673
New +$718K
CMRX
39
DELISTED
Chimerix, Inc.
CMRX
$771K 0.76%
+19,152
New +$649K
XNCR icon
40
Xencor
XNCR
$2.15B
$717K 0.71%
+44,698
New +$518K
AVDL
41
DELISTED
Avadel Pharmaceuticals
AVDL
$716K 0.71%
+41,788
New +$597K
TLPH icon
42
Talphera
TLPH
$63.8M
$673K 0.67%
+4,998
New +$648K
CBST
43
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$655K 0.65%
+6,502
New +$505K
ACHN
44
DELISTED
Achillion Pharmaceuticals
ACHN
$613K 0.61%
+50,000
New +$611K
ARWR icon
45
Arrowhead Research
ARWR
$12.5B
$606K 0.6%
+82,133
New +$559K
NPSP
46
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$553K 0.55%
+15,471
New +$462K
ILMN icon
47
CALL
Illumina
ILMN
$34.4B
$550K 0.54%
+257
New +$45.3K
EPZM
48
DELISTED
Epizyme, Inc
EPZM
$535K 0.53%
+28,339
New +$662K
AGIO icon
49
Agios Pharmaceuticals
AGIO
$2.05B
$495K 0.49%
+4,416
New +$394K
INCY icon
50
CALL
Incyte
INCY
$25.9B
$481K 0.48%
+886
New +$57.9K
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q4 2014 Portfolio in Review

Q4 2014 is the first quarter with a 13F filing on record for Opus Point Partners Management, which disclosed 57 positions worth $101M. Its ten largest holdings account for 38% of the portfolio.

Its largest position is ProShares Ultra NASDAQ Biotechnology: 76,368 shares worth $4.79M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, followed by Miscellaneous.

  • Opus Point Partners Management's largest Q4 2014 buy was ProShares Ultra NASDAQ Biotechnology: 76,368 shares worth $4.79M.
  • Opus Point Partners Management's ten largest holdings make up 38% of its $101M portfolio in Q4 2014.
  • Opus Point Partners Management disclosed 57 positions in Q4 2014, its first 13F filing on record.

Based on Opus Point Partners Management's 13F filing for Q4 2014, filed 17 Feb 2015.